- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
CytoViva Reveals Distinction Between Calcifying Nanoparticles and Inorganic Crystal
Research is finding evidence that may solve one of the great puzzles of 21st Century medicine using a new microscopy technology known as CytoViva.
Researchers at Mayo Clinic successfully isolated nanoparticles from
human kidney stones and calcified aortas. The findings, which appear in the
Journal of Investigative Medicine, are significant because they move
researchers a step closer to understanding whether nanoparticles can
contribute to the pathogenesis of a variety of diseases. Recently, for the
first time the Mayo Clinic investigators visualized their nanoparticle
isolates in real-time using CytoViva.
In November, a team of scientists at Nanobac Pharmaceuticals utilizing
CytoViva released the first-ever live video footage of calcifying
nanoparticles. Calcification occurs in many diseases listed on the leading-
cause-of-death list such as cardiovascular and kidney disease.
Calcification is also linked to chronic inflammation in atherosclerosis and
end-stage renal disease, but it is unclear how this occurs. Nanoparticle
calcification is being studied because it is believed to play a basic role
in calcifying diseases ranging from heart disease to kidney stones to
"We used a new, very high definition microscope system," explained Dr.
Neva Ciftcioglu, Science Director of Nanobac Pharmaceuticals, which
produced the video. "Before these technologies were created recently, we
had to chemically treat the nanoparticles to see below the 200 nanometer
threshold, which kept us from observing live processes."
The new video was first unveiled at a recent invitation-only Auburn
University conference of leading microscopy and biomedical scientists,
organized by the Fetzer Memorial Trust. Fetzer specializes in supporting
leading-edge medical technologies and has been collaborating with Nanobac
Pharmaceuticals on this project since early 2006.
CytoViva, which won an R&D 100 award last year, is a new product
combining fluorescence and high resolution optical imaging to create a new,
unparalleled level of microscopy performance. The unique system allows
researchers to view both fluorescent and non-fluorescent sample structure
simultaneously, in real time and at high resolution.
About CytoViva, Inc.
Auburn, AL-based, CytoViva, Inc., is a subsidiary of Aetos
Technologies, Inc., a privately held technology development company founded
to bridge the gap between university-based research and the commercial
For more information, please click here
Copyright © PR Newswire Association LLC.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016
UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016
Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016
Leti IEDM 2016 Paper Clarifies Correlation between Endurance, Window Margin and Retention in RRAM for First Time: Paper Presented at IEDM 2016 Offers Ways to Reconcile High-cycling Requirements and Instability at High Temperatures in Resistive RAM December 6th, 2016
Infrared instrumentation leader secures exclusive use of Vantablack coating December 5th, 2016